论文部分内容阅读
新药在临床应用前应认真进行疗效与安全检验,再经临床对人体进行可靠性与安全研究,经审定合格后方可普遍应用。临床研究必须遵循赫尔辛基宣言规定的道德标准。新的诊断与治疗仪器在临床应用前也必须进行这样的工作。纤维内镜就属于这种范围。纤维内镜术与药物疗法有所不同,药物疗法的危险是潜在的若干毒性作用,纤维内镜检查则是医师缺乏有关检查适应症和禁忌症的知识;缺乏技巧术与专门培训。
Before the clinical application of the new drug, the efficacy and safety test should be carefully conducted, and then the reliability and safety of the human body should be studied in the clinic. After being approved, the new drug can be generally applied. Clinical research must follow the ethical standards set by the Helsinki Declaration. New diagnostic and therapeutic instruments must also perform such work before clinical application. Fibrous endoscopy falls into this category. Fiberoptic endoscopy differs from drug therapy in that the risks of drug therapy are potentially toxic, and fiber endoscopy is the lack of knowledge of physicians to examine indications and contraindications; lack of skills and specialized training.